---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-058821"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2024-07-03T23:59:59+00:00"
generated_at: "2026-05-31T23:39:02.206454+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M

## Summary
- Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.
- Net loss $3.7M ($0.07/sh) vs $10.6M ($0.21/sh); cash $2.5M at Dec 31, 2023.
- MENA region and U.S. sales drove growth; disposed of Japanese JV equity interest.
- Inventory shortage impacted Q4 2023 sales; backlog ~$4.6M as of May 24, 2024; now resolved.

## SEC filing metadata
- accession: 0001213900-24-058821
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2024-07-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390024058821/0001213900-24-058821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390024058821/ea0207151-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-058821
- JSON: https://secwatch.observer/filing/0001213900-24-058821.json
- Plain text: https://secwatch.observer/filing/0001213900-24-058821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.